{"data":{"type":"company_profile_ai","id":130590,"entity_id":"wefunder:company:130590","attributes":{"canonical_url":"https://wefunder.com/invvax","retrieval_urls":{"canonical":"https://wefunder.com/invvax","json":"https://wefunder.com/invvax.json","markdown":"https://wefunder.com/invvax.md","ai_json":"https://wefunder.com/invvax.ai.json","ai_text":"https://wefunder.com/invvax.ai.txt","changelog_json":"https://wefunder.com/invvax.changelog.json","schema":"https://wefunder.com/.well-known/ai-profile-schema.json"},"updated_at":"2026-06-22T05:03:42Z","generated_at":"2026-06-22T18:30:41Z","profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"company":{"id":130590,"entity_id":"wefunder:company:130590","slug":"invvax","name":"InvVax","tagline":"We use a new genetics platform to develop better vaccines for flu, COVID-19, etc","location":"Pasadena, CA","website":"https://www.inv-vax.com","total_amount_raised":124203,"total_investors":120,"is_funded":true,"is_active":true},"key_claims":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 124203","citation":"https://wefunder.com/invvax#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-22T05:03:42Z","as_of":"2026-06-22T18:30:41Z","confidence":"high"},"observed_at":"2026-06-22T05:03:42Z","expires_at":"2026-06-23T05:03:42Z"},{"claim_id":"claim-total-investors","text":"Total investors: 120","citation":"https://wefunder.com/invvax#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-22T05:03:42Z","as_of":"2026-06-22T18:30:41Z","confidence":"high"},"observed_at":"2026-06-22T05:03:42Z","expires_at":"2026-06-23T05:03:42Z"}],"verified_facts":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 124203","citation":"https://wefunder.com/invvax#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-22T05:03:42Z","as_of":"2026-06-22T18:30:41Z","confidence":"high"},"observed_at":"2026-06-22T05:03:42Z","expires_at":"2026-06-23T05:03:42Z"},{"claim_id":"claim-total-investors","text":"Total investors: 120","citation":"https://wefunder.com/invvax#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-22T05:03:42Z","as_of":"2026-06-22T18:30:41Z","confidence":"high"},"observed_at":"2026-06-22T05:03:42Z","expires_at":"2026-06-23T05:03:42Z"}],"company_claims":{"tagline":"We use a new genetics platform to develop better vaccines for flu, COVID-19, etc","story":"*To our knowledge, this is the only universal flu vaccine targeting invariant sequence of influenza, but there could be, in theory, others that we do not know about.Source: Vision Research Reports.To our knowledge, we are the only company focused on invariance. There could be others we do not know about.Forward-looking projections are not guaranteed.Forward-looking projections are not guaranteed.","quick_facts":["Huge global market for these vaccines: Universal flu - $22B; COVID-19 - $5B","Chance to make an enormous societal impact","Patented durable and universal flu vaccine","Major smashes: Moderna, BioNTech, Novavax: Invest in the next one!","Backed by Life Science Angels - #1 US angel group (CB Insights), Sand Hill Angels, Tech Coast Angels","Funded by the DoD and the NSF"]},"computed_metrics":{"total_amount_raised":124203,"total_investors":120,"team_size":3,"featured_investor_count":1,"faq_count":5,"recent_post_count":10},"quick_facts":[{"claim_id":"claim-fact-1","value":"Huge global market for these vaccines: Universal flu - $22B; COVID-19 - $5B","citation":"https://wefunder.com/invvax#claim-fact-1","observed_at":"2026-06-22T05:03:42Z","expires_at":"2026-06-29T05:03:42Z"},{"claim_id":"claim-fact-2","value":"Chance to make an enormous societal impact","citation":"https://wefunder.com/invvax#claim-fact-2","observed_at":"2026-06-22T05:03:42Z","expires_at":"2026-06-29T05:03:42Z"},{"claim_id":"claim-fact-3","value":"Patented durable and universal flu vaccine","citation":"https://wefunder.com/invvax#claim-fact-3","observed_at":"2026-06-22T05:03:42Z","expires_at":"2026-06-29T05:03:42Z"},{"claim_id":"claim-fact-4","value":"Major smashes: Moderna, BioNTech, Novavax: Invest in the next one!","citation":"https://wefunder.com/invvax#claim-fact-4","observed_at":"2026-06-22T05:03:42Z","expires_at":"2026-06-29T05:03:42Z"},{"claim_id":"claim-fact-5","value":"Backed by Life Science Angels - #1 US angel group (CB Insights), Sand Hill Angels, Tech Coast Angels","citation":"https://wefunder.com/invvax#claim-fact-5","observed_at":"2026-06-22T05:03:42Z","expires_at":"2026-06-29T05:03:42Z"},{"claim_id":"claim-fact-6","value":"Funded by the DoD and the NSF","citation":"https://wefunder.com/invvax#claim-fact-6","observed_at":"2026-06-22T05:03:42Z","expires_at":"2026-06-29T05:03:42Z"}],"latest_fundraise":{"id":79868,"entity_id":"wefunder:fundraise:79868","state":"successful","offering_type":"4(a)(6)","structure":"convertible_note","testing_the_waters":false,"can_invest_now":false,"funding_started_at":"2023-07-20T17:29:51Z","funding_closed_at":"2024-04-30T04:03:29Z"},"investor_memos":[],"team":[{"id":3391431,"entity_id":"wefunder:company_role:3391431","name":"Arthur Young","title":"CEO","role":"founder","profile_url":"https://wefunder.com/arthur.young.1"},{"id":4075815,"entity_id":"wefunder:company_role:4075815","name":"Nima Shiva","title":"Head of Business Development","role":"employee","profile_url":"https://wefunder.com/nima.shiva"},{"id":3395494,"entity_id":"wefunder:company_role:3395494","name":"Olga Petrauskene","title":"Director","role":"employee"}],"featured_investors":[{"id":6120,"entity_id":"wefunder:company_investor_profile:6120","name":"Priya Balachandran","profile_url":"https://wefunder.com/priyabalachandran","endorsement_quote":"InvVax is fundamentally changing the way in which antiviral vaccines are developed. Leveraging years of technical and commercial experience in the space, the InvVax team has developed a breakthrough platform that significantly increases the vaccine hit rate against current, emerging and future variants of viruses such as Influenza, Hepatitis and SARS-COV-2. InvVax is collaborating with leading global researchers in the space to apply their best knowledge and move the technology to the next phase of commercialization \u0026amp; implementation. The platform can be extended to address rapid vaccine development for other viruses and future pathogens. Arthur Young, with his deep knowledge in viral genomics, Nima Shiva, with his proven track record in the biotechnology entrepreneurial space and Olga Petrauskene, with her extensive experience in viral diagnostics, create an outstanding team to bring forth a compelling platform to address the public health threat of viral infectious diseases globally."}],"relationships":[{"source_entity_id":"wefunder:company:130590","relation":"has_team_member","target_entity_id":"wefunder:user:2830583","target_url":"https://wefunder.com/arthur.young.1"},{"source_entity_id":"wefunder:company:130590","relation":"has_team_member","target_entity_id":"wefunder:user:5030432","target_url":"https://wefunder.com/nima.shiva"},{"source_entity_id":"wefunder:company:130590","relation":"has_team_member","target_entity_id":"wefunder:company_role:3395494"},{"source_entity_id":"wefunder:company:130590","relation":"has_featured_investor","target_entity_id":"wefunder:user:3616218","target_url":"https://wefunder.com/priyabalachandran"},{"source_entity_id":"wefunder:company:130590","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:172797","target_url":"https://wefunder.com/feed/172797"},{"source_entity_id":"wefunder:company:130590","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:172242","target_url":"https://wefunder.com/feed/172242"},{"source_entity_id":"wefunder:company:130590","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:171398","target_url":"https://wefunder.com/feed/171398"},{"source_entity_id":"wefunder:company:130590","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:171251","target_url":"https://wefunder.com/feed/171251"},{"source_entity_id":"wefunder:company:130590","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:170436","target_url":"https://wefunder.com/feed/170436"},{"source_entity_id":"wefunder:company:130590","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:170186","target_url":"https://wefunder.com/feed/170186"},{"source_entity_id":"wefunder:company:130590","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:170038","target_url":"https://wefunder.com/feed/170038"},{"source_entity_id":"wefunder:company:130590","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:169830","target_url":"https://wefunder.com/feed/169830"},{"source_entity_id":"wefunder:company:130590","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:169726","target_url":"https://wefunder.com/feed/169726"},{"source_entity_id":"wefunder:company:130590","relation":"has_recent_update","target_entity_id":"wefunder:feed_item:169104","target_url":"https://wefunder.com/feed/169104"},{"source_entity_id":"wefunder:company:130590","relation":"has_latest_fundraise","target_entity_id":"wefunder:fundraise:79868"}],"faq":[{"question":"Given the amount of funding you've raised and the length of time you have been around, what can you offer in the way of confidence of the 36 month strategy to an IPO or partnership (and why those two as a target in 3 years time?). Sorry to sound skeptical but it's a very diffe...","answer":"Hi Ethan, of note, we have begun outreach to large pharmaceutical companies seeking partnerships or licensing of our technology, and we have already met with interest from a couple of overseas large Pharma. They would like to see some data comparing mRNA to our viral vector, as the former is such a hot thing right now! (as it is a potent biological tool for vaccines, which I'm sure you know from COVID). We've obtained funding to execute that very experiment, and are already underway! We're co..."},{"question":"Hey Arthur, this is a super cool company. Love what you’re focused on. Congratulations on the recent Duke grant win. Way to go! Would you please consider answering a few questions that I have? I noticed that the intention for some of the money resulting from this capital raise...","answer":"Hi Justin, Thanks for these great questions! We've been branching out to other pathogens beside flu virus for a few reasons. First, we've completed all the preclinical proof-of-concept studies for our flu vaccine with the exception of two experiments, which we are going to do with our Duke grant. Since we're outsourcing these mouse studies, and since beyond that point, it's a lot of \"waiting\" around while our product goes through the long regulatory process, there's a lot of time and opportun..."},{"question":"Hello, As a critical care respiratory therapist, now physician assistant, I have dealt with so many of these respiratory viruses; h1n1, covid, other flu strains dealing with the sickest of patients. This research/tech could be ground breaking if you are able to succeed. You me...","answer":"Hi Adam, Sorry for the delayed response. We do have two patents that have been granted for our flu vaccine, which is protecting the eleven sequence stretches in flu which are invariant (cannot be mutated without lethal consequence to virus). These sequence stretches make up the composition of our vaccine, such that it is not susceptible to viral mutational escape like all other flu vaccines are. There are a few possible answers to your question about why we believe we will succeed. First, we ..."},{"question":"Does your patent apply to the technology in general, or just to your flu vaccine?","answer":"Hi Michael, Thanks for asking. Our two patents are on the flu vaccine composition. It's very difficult to patent a method these days. However, we've got flu covered because we know no one else is going to find superior (or equal) targets, since we surveyed the whole genome and took the 11 best targets. As for the technological platform, we're underway in applying it to other viruses to meet unmet medical needs. The platform is quite labor-intensive and tricky, which makes it difficult for oth..."},{"question":"Hey Arthur, me again. It was really exciting to see the company's recent update, great work! And thank you for the detailed answer below. Would you mind commenting on how many months of runway InnVax has given it's approximate burn rate going forward? It's unclear to me exactl...","answer":"Hey Justin, We're being powered mostly by federal grants right now, so our runway is based on that. We're burning approx. $60k a month, and are guaranteed at least 2.5 more years from grants. But, it's a relatively fluid situation; for example, we expect to receive a new 2 year grant pretty soon."}],"recent_posts":[{"id":172797,"entity_id":"wefunder:feed_item:172797","title":"InvVax Wefunder campaign closing soon!","preview":"https://www.cnn.com/2024/04/17/opinions/bird-flu-pandemic-threat-covid-mammals-yassif/index.htmlIt's shocking to say this, but we could be standing on the precipice of yet another pandemic. Influenza H5N1, a.k.a. \"bird flu,\" normally infects wild birds (such as ducks, geese, etc.) and farmed chickens, but does not normally infect mammals, including humans. However, there have been a couple of outbreaks of H5N1 among humans in the recent past. H5N1 originated in Hong Kong in 1997, and has caus...","published_at":"2024-04-22T20:05:18Z","canonical_url":"https://wefunder.com/feed/172797"},{"id":172242,"entity_id":"wefunder:feed_item:172242","title":"InvVax makes it first foray into cancer!","preview":"I'm excited to announce that we've expanded our pipeline into cancer! This will be very early-stage R\u0026D. As a graduate student (yes, over 20 years ago), I had an idea to treat cancer by exploiting a universal feature of all cancers, which is the aberrant regulation of the Rb-E2F pathway. (This was the main topic of my PhD research.) E2F is a protein that drives cells into DNA replication, and Rb restrains E2F. Thus, E2F is the \"gatekeeper\" that determines whether a cell divides or not, and Rb...","published_at":"2024-04-05T18:40:35Z","canonical_url":"https://wefunder.com/feed/172242"},{"id":171398,"entity_id":"wefunder:feed_item:171398","title":"Critical comparison of optimal flu vaccine modality","preview":"Greetings everyone,We're happy to say that our pivotal flu vaccine mouse study with Duke University is underway! Funded by an NIH grant through the Duke CIVICs program (Collaborative Influenza Vaccine Innovation Centers), we're comparing our adenoviral-vectored flu vaccine, already proven to work well, to mRNA as well as to peptides. As you almost certainly know, mRNA was the difference-maker that got the COVID-19 vaccine into clinics and played a major role in ending the pandemic. Many compa...","published_at":"2024-03-08T22:30:42Z","canonical_url":"https://wefunder.com/feed/171398"},{"id":171251,"entity_id":"wefunder:feed_item:171251","title":"A new modality: Antibodies as prevention","preview":"Announcing solid progress toward our goal!Hello everyone,We're pleased to report substantial progress on our stable prophylactic antibodies (spAbs) work!As you might know, we received funding from the National Science Foundation just over two years ago to work on a project which is only tangentially related to our vaccine work, but is arguably the most exciting work in our pipeline. Namely, we are designing an antibody (Ab) backbone that is so extremely stable that our Abs can be given prophy...","published_at":"2024-03-02T19:18:59Z","canonical_url":"https://wefunder.com/feed/171251"},{"id":170436,"entity_id":"wefunder:feed_item:170436","title":"New COVID-19 Vaccine is Subpar","preview":"The news is out\u0026nbsp;- this year's COVID-19 vaccine is just 54% effective:\u0026nbsp;https://www.statnews.com/2024/02/01/updated-covid-vaccine-effectiveness/That puts it in the range of the annual flu shot, which averages 40% effectiveness, at times is as high as 60%, and sometimes is as low as 20%. What does that mean, from a mathematical standpoint? (As an aside, you might hear the word \"effectiveness\" on occasion and other times, \"efficacy.\" The former is more a measure of natural world data, w...","published_at":"2024-02-08T18:43:55Z","canonical_url":"https://wefunder.com/feed/170436"},{"id":170186,"entity_id":"wefunder:feed_item:170186","title":"KingsCrowd Capital's Investment into InvVax","preview":"Hello everyone,I'm excited to share some groundbreaking news with our InvVax community. KingsCrowd Capital has made a solid investment in InvVax during our current Wefunder round, and we've been awarded a stellar 4.3 rating on their platform. This is a monumental endorsement of our work and vision at InvVax.Understanding KingsCrowd CapitalKingsCrowd Capital is at the forefront of equity crowdfunding analysis, providing independent, AI-powered ratings and analytics for the online private marke...","published_at":"2024-01-24T18:55:28Z","canonical_url":"https://wefunder.com/feed/170186"},{"id":170038,"entity_id":"wefunder:feed_item:170038","title":"InvVax Video Update","preview":"Hi everyone,I'm thrilled to share a recent video interview that highlights the innovative work we're undertaking at InvVax. This conversation is an engaging overview of our mission and the exciting investment opportunity available to those who wish to join us in this groundbreaking venture.In the video, you'll hear about our unique approach at InvVax - tackling the challenge of rapidly mutating viruses like influenza and COVID-19. We focus on developing vaccines that target crucial, unchangea...","published_at":"2024-01-17T20:54:10Z","canonical_url":"https://wefunder.com/feed/170038"},{"id":169830,"entity_id":"wefunder:feed_item:169830","title":"InvVax's Year in Review: Pioneering Partnerships, Innovative Research, and Grant Triumphs in 2023","preview":"Hello Everyone,As we step into a new year, I want to share a personal reflection on the significant milestones and progress we've made at InvVax in 2023. It's been a year of growth, discovery, and collaboration, and I'm proud to recount these highlights with you.Firstly, we welcomed Nima Shiva, MBA, as our new Head of Business Development. Nima's impressive background, with a Bachelor’s in Neuroscience and Physiology from the University of California, San Diego, and an MBA from the Marshall S...","published_at":"2024-01-09T19:06:36Z","canonical_url":"https://wefunder.com/feed/169830"},{"id":169726,"entity_id":"wefunder:feed_item:169726","title":"Elevating Impact in Global Health Innovation","preview":"It is very difficult, in this season of gladness and joy, to share with you this tragic story of a beautiful young girl, fully healthy, who perished just one day after being diagnosed with the flu.Read Article at Today.comStories like these are a sober reminder – indeed, a spark lit under me –motivating me to work double overtime to make the InvVax product a commercial reality. If there is a girl like Teresa, there are 650,000 more who succumb each year to the flu worldwide; and what is my ti...","published_at":"2023-12-29T19:55:36Z","canonical_url":"https://wefunder.com/feed/169726"},{"id":169104,"entity_id":"wefunder:feed_item:169104","title":"Exciting Update: InvVax Early Bird Opportunity Extended!","preview":"Hello Everyone!I hope this message finds you well. I'm thrilled to share some exciting news with you regarding our ongoing Wefunder campaign.As many of you know, we launched our campaign with an early bird offer that has garnered significant interest and support. In response to this overwhelming demand and to show our appreciation for your enthusiasm, we've decided to extend our early bird terms.Originally, our early bird offer included a 35% discount and a $7.5 million pre-money valuation ca...","published_at":"2023-12-06T13:01:38Z","canonical_url":"https://wefunder.com/feed/169104"}],"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-22T18:30:41Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-22T05:03:42Z","as_of":"2026-06-22T18:30:41Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-22T05:03:42Z","as_of":"2026-06-22T18:30:41Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2026-02-12T18:21:04Z","as_of":"2026-06-22T18:30:41Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2026-02-12T18:21:04Z","as_of":"2026-06-22T18:30:41Z","confidence":"medium"}}}}}}